{"id":58466,"date":"2023-11-23T19:05:16","date_gmt":"2023-11-23T18:05:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dermatology-collaboration-and-licensing-deals-analysis-report-and-directory-2016-2023-researchandmarkets-com\/"},"modified":"2023-11-23T19:05:16","modified_gmt":"2023-11-23T18:05:16","slug":"dermatology-collaboration-and-licensing-deals-analysis-report-and-directory-2016-2023-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dermatology-collaboration-and-licensing-deals-analysis-report-and-directory-2016-2023-researchandmarkets-com\/","title":{"rendered":"Dermatology Collaboration and Licensing Deals Analysis Report and Directory 2016-2023 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Dermatology Collaboration and Licensing Deals 2016-2023”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a>
<\/a><\/p>\n

\nFully revised and updated, the report provides details of dermatology deals from 2016 to 2023. Dermatology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the dermatology deals entered into by the worlds leading biopharma companies.<\/p>\n

\nThe report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.<\/p>\n

\nUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.<\/p>\n

\nThis report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.<\/p>\n

\nThe report also includes numerous table and figures that illustrate the trends and activities in dermatology deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type.<\/p>\n

\nEach deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.<\/p>\n

\nChapter Highlights<\/strong><\/p>\n

\nThe initial chapters of this report provide an orientation of dermatology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in dermatology dealmaking.<\/p>\n

\nChapter 3 covers the financial deal terms for deals signed in the dermatology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.<\/p>\n

\nChapter 4 provides a review of the top 25 most active biopharma companies in dermatology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.<\/p>\n

\nChapter 5 provides a comprehensive and detailed review of dermatology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.<\/p>\n

\nChapter 6 provides a comprehensive directory of dermatology deals listed by theraeutic target.<\/p>\n

\nKey benefits<\/strong><\/p>\n

\nDermatology Collaboration and Licensing Deals provides the reader with the following key benefits:<\/strong><\/p>\n